Jun 07, 2022 / 03:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the ADA Investor Update. (Operator Instructions) As a reminder, today's conference is being recorded.
And I would now like to turn the conference over to our host, Lauren Zierke. Please go ahead.
Lauren Zierke;Senior Director of Investor Relations -
Good morning. Thank you for joining us for Eli Lilly and Company's Obesity & Diabetes Update at ADA. I'm Lauren Zierke, Senior Director of Investor Relations. Joining me on today's call are Mike Mason, President of Lilly Diabetes; Dr. Dan Skovronsky, Chief Scientific and Medical Officer; Dr. Jeff Emmick, Vice President of Diabetes Product Development; Dr. Ruth Gimeno, Vice President of Diabetes Research and Clinical Investigation; and Jamie Croaning, Global Development Leader for Tirzepatide.
During this conference, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 2. Additional
Eli Lilly and Co Diabetes & Obesity Update at ADA Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot